Eargo (NASDAQ:EAR) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Insider & Institutional Ownership
Get Eargo alerts:
69.7% of Eargo shares are owned by institutional investors. Comparatively, 50.6% of Surgalign shares are owned by institutional investors. 11.0% of Surgalign shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Eargo and Surgalign, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eargo 0 0 4 0 3.00
Surgalign 0 0 5 0 3.00
Eargo currently has a consensus price target of $45.33, indicating a potential upside of 102.20%. Surgalign has a consensus price target of $4.00, indicating a potential upside of 158.06%. Given Surgalign’s higher probable upside, analysts clearly believe Surgalign is more favorable than Eargo.
Top 10 Medical Stocks To Invest In Right Now: Protalix BioTherapeutics, Inc.(PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The companys product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-106, an oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and PRX-112, an orally administered glucocerebrosidase enzyme (GCD) for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD produced and encapsulated within carrot cells. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.
Advisors’ Opinion:
- [By Alex Sirois]
Ameresco commands a 16.9% share of that market based on revenue. While it may not be poised to spike in price immediately, it certainly is in a strong position to do so over a longer period.
Clean Energy Stocks for ‘Code Red’: Array Technologies (ARRY) Source: Shutterstock
You probably guessed that Array Technologies operates within the solar power industry based on its name. The New Mexico company manufactures ground mounting systems used for solar panels. Succinctly put, its mounting systems angle solar panels to best absorb the sun’s energy.
- [By Howard Smith (TMFBuilt2Last)]
A new brief released by the U.S. Department of Energy outlined plans to achieve President Joe Biden’s goal for a carbon pollution-free power generation sector by 2035, and Array Technologies (NASDAQ:ARRY) is one company that could greatly benefit. That helped the company’s stock jump Wednesday, with shares trading up 10% as of 3:30 p.m. EDT.
- [By Beth McKenna]
Shares of Array BioPharma (NASDAQ:ARRY) gained 22.9% last month, according to data from S&P Global Market Intelligence. The stock is up 63% in 2019 through March 5.
Top 10 Medical Stocks To Invest In Right Now: Core Laboratories N.V.(CLB)
Core Laboratories N.V., incorporated on July 8, 1994, is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields. The Company has over 70 offices in over 50 countries. The Company operates in three segments: Reservoir Description, Production Enhancement and Reservoir Management. These segments provide different services and products and utilize different technologies for improving reservoir performance, and increasing oil and gas recovery from new and existing fields. The Company offers its services through its global network of offices. The Company manufactures products primarily in over four facilities for distribution on a global basis.
Reservoir Description
The Company’s Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples. The Company provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. The Company provides services that characterize the porous reservoir rock and over three reservoir fluids. Services relating to these fluids include determining quality and measuring quantity of the fluids and their derived products. This includes determining the value of different crude oil and natural gases by analyzing the individual components of complex hydrocarbons. These data sets are used by oil companies to determine the efficient method by which to recover, process and refine these hydrocarbons to produce the value added to crude oil and natural gas.
The Company analyzes samples of reservoir rocks for their porosity, which determines reservoir storage capacity, and for their permeability, which defines the ability of the fluids to flow through the rock. These measurements are used to determine how much oil and gas are present in a reservoir and the rates at which the oil and gas can be produced. The Company also uses its services and technologies to correlate the reservoir description data to wireline logs and seismic data by determining the different acoustic velocities of reservoir rocks containing water, oil and natural gas. These measurements are used in conjunction with the Company’s reservoir management services to develop programs to produce oil and gas from the reservoir.
Production Enhancement
The Company’s Production Enhancement segment includes products and services relating to reservoir well completions, perforations, stimulations and production. The Company provides integrated services to evaluate the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects. The Company provides diagnostic services and products to help optimize completion and reservoir operations, and field development strategies in order to increase recoverable reserves. The Company provides services that are used by others to develop and optimize hydraulic fracturing and field flood projects. The Company’s data on rock type and strength are critical for determining the proper design of the hydraulic fracturing job. In addition, the Company’s testing indicates whether the fluid slurry is compatible with the reservoir rock so that damage does not occur that would restrict production. The Company also provides testing of various propping agents and software to help pick the best proppant based on net present value calculations of client investments. The Company’s ZERO WASH tracer technology is used to determine that the proppant material is properly placed in the fracture.
SPECTRACHEM is the Company’s technology, which is developed for optimizing hydraulic fracture performance. SPECTRACHEM is used to aid operators in determining the efficiency of the fracture fluids used. SPECTRACHEM tracers allow operators to evaluate the quantity of fracture fluid that returns to the wellbore during the clean-up period after a hydraulic fracturing event. This technology also allows the Company’s clients to evaluate load recovery, gas breakthrough, fluid leak-off and breaker efficiency, all of which are factors for optimizing oil and/or natural gas production after the formation is hydraulically fractured. The SPECTRACHEM Plus service determines the effectiveness and efficiency of the hydraulic fracture stimulation of long multi-stage horizontal wells in oil- and gas-shale plays throughout North America.
The Company’s completion monitoring system, COMPLETION PROFILER, helps to determine flow rates from reservoir zones after they have been hydraulically fractured. The Company’s FLOWPROFILER service, a hydrocarbon-based tracer technology, which is a further development of the Company’s patented SPECTRACHEM technology, quantifies the hydrocarbon production from discrete segments in multi-stage horizontal well completions and stimulations in unconventional tight-oil or gas plays. The Company has tracers used for oil reservoirs, which are different from the Company’s tracers used for gas reservoirs. FLOWPROFILER technology employs a hydrocarbon-soluble tracer and water-soluble tracer introduced into specific and isolated stages via the stimulating proppant stream.
The Company conducts dynamic flow tests of the reservoir fluids through the reservoir rock, at actual reservoir pressure and temperature, to realistically simulate the actual flooding of a producing zone. The Company uses technologies, such as its Saturation Monitoring by the Attenuation of X-rays (SMAX), to help design the enhanced recovery project. After a field flood is initiated, the Company is involved in monitoring the progress of the flood. The Company’s PACKSCAN technology is used as a tool to evaluate gravel pack effectiveness in an unconsolidated reservoir. PACKSCAN measures the density changes in the area around the tool and is designed to observe the changes within the gravel pack annulus to verify the completeness of the gravel pack protection of the wellbore without any additional rig time.
The Company’s High Efficiency Reservoir Optimization (HERO), SUPERHERO and SUPERHERO Plus perforating systems enhance reservoir performance. The SUPERHERO and SUPERHERO Plus perforating systems complement the Company’s HERO line, and are designed to optimize wellbore completions and stimulation programs in oil- and gas-shale reservoirs. SUPERHERO and SUPERHERO Plus charges can eliminate the ineffective perforations that would otherwise limit daily oil and natural gas production and hinder the optimal fracture stimulation programs needed for prolific production from the Bakken, Eagle Ford, Marcellus, Niobrara and similar oil- and gas-shale formations.
The Company’s Horizontal Time-Delayed Ballistics Actuated Sequential Transfer (HTD-BLAST) perforating system is a technology useful for the perforation of extended-reach horizontal completions in the Bakken, Eagle Ford, and other shale formations. The HTD-BLAST perforating system can be deployed via coiled tubing and enables over 10 perforating events, beginning at the farthest reaches, or toe regions, of extended-reach horizontal wells, or over 30 perforating events in vertical wellbores. The Company also offers KODIAK Enhanced Perforating Systems energetic technology. The Company’s X-SPAN and GTX-SPAN casing patches are supported by the Company’s technical services personnel. These systems are capable of performing in high pressure oil and gas environments, and are used to seal non-productive reservoir zones from the producing wellbore.
Reservoir Management
The Company’s Reservoir Management segment combines and integrates information from reservoir description and production enhancement services to increase production and improve recovery of oil and gas from the Company’s clients’ reservoirs. The Company is involved in various large-scale reservoir management projects. It also develops and provides industry consortium studies to provide critical reservoir information to a spectrum of clients, such as the Company’s multi-client, basin-wide reservoir optimization projects conducted in North America and international settings. Many of these studies examine unconventional reservoirs. The Company engineers and manufactures permanent real-time reservoir monitoring equipment that is installed in the reservoir for the Company’s oil and gas company clients. The Company’s non-electronic ERD Pressure and Temperature sensors provide real-time data, which is used by drilling engineers to make real-time decisions, production engineers to optimize production, and reservoir engineers to prove up models and obtain a picture of the reservoir over time.
Advisors’ Opinion:
- [By Joseph Griffin]
COPYRIGHT VIOLATION WARNING: “Core Laboratories (CLB) Shares Sold by Eagle Asset Management Inc.” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at www.tickerreport.com/banking-finance/4197965/core-laboratories-clb-shares-sold-by-eagle-asset-management-inc.html.
- [By Travis Hoium, Jason Hall, and Matthew DiLallo]
Three of our Foolish contributors put their heads together to outline what the best oil stocks are today given the market’s trends, and Core Laboratories (NYSE:CLB), Anadarko Petroleum (NYSE:APC), and Ensco (NYSE:ESV) bubbled to the top. They’re well positioned in the market and may even provide a great value for long-term investors.
Top 10 Medical Stocks To Invest In Right Now: GreenSky, Inc.(GSKY)
GreenSky, Inc., a technology company, that enables promotional financing at the point of sale for merchants, consumers, and bank partners. It offers a proprietary technology infrastructure that supports the full transaction lifecycle, including credit application, underwriting, real-time allocation to bank partners, document distribution, funding, settlement, and servicing functions. The company was founded in 2006 and is headquartered in Atlanta, Georgia.
Advisors’ Opinion:
- [By Ethan Ryder]
GreenSky (NASDAQ:GSKY) had its price target raised by SunTrust Banks to $14.00 in a research note released on Wednesday morning, The Fly reports. They currently have a buy rating on the stock. SunTrust Banks also issued estimates for GreenSky’s Q1 2019 earnings at $0.07 EPS, Q2 2019 earnings at $0.15 EPS, Q3 2019 earnings at $0.19 EPS, Q4 2019 earnings at $0.16 EPS, FY2019 earnings at $0.58 EPS and FY2020 earnings at $0.71 EPS.
- [By Shane Hupp]
Verition Fund Management LLC purchased a new position in GreenSky Inc (NASDAQ:GSKY) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 16,166 shares of the company’s stock, valued at approximately $342,000.
Top 10 Medical Stocks To Invest In Right Now: Team, Inc.(TISI)
Introduction. Unless otherwise indicated, the terms “Team, Inc.,” “Team,” “the Company,” “we,” “our” and “us” are used in this report to refer to Team, Inc., to one or more of our consolidated subsidiaries or to all of them taken as a whole. We are incorporated in the State of Delaware and our company website can be found at www.teaminc.com. Our corporate headquarters is located at 13131 Dairy Ashford, Suite 600, Sugar Land, Texas, 77478 and our telephone number is (281) 331-6154. Our stock is traded on the New York Stock Exchange (“NYSE”) under the symbol “TISI.” On November 10, 2015, we announced a change of our fiscal year end to December 31 of each calendar year from May 31. This transition report is for the seven-month transition period of June 1, 2015 through December 31, 2015. Advisors’ Opinion:
- [By Motley Fool Transcribers]
Team Inc (NYSE:TISI)Q4 2018 Earnings Conference CallMarch 13, 2019, 10:00 a.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
- [By Ethan Ryder]
Team, Inc. (NYSE:TISI) has earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $26.00.
- [By Ethan Ryder]
Bank of New York Mellon Corp increased its position in shares of Team, Inc. (NYSE:TISI) by 0.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 336,526 shares of the business services provider’s stock after acquiring an additional 2,905 shares during the period. Bank of New York Mellon Corp’s holdings in Team were worth $7,773,000 as of its most recent filing with the Securities and Exchange Commission.
Top 10 Medical Stocks To Invest In Right Now: Brookfield Renewable Corporatio(BEPC)
Brookfield Renewable Corporation owns and operates a portfolio of renewable energy power generating facilities primarily in Brazil, Colombia, the United States, and Europe. It operates hydroelectric, wind, and solar power plants with an installed capacity of approximately 12,812 megawatts. The company was incorporated in 2019 and is headquartered in New York, New York.
Advisors’ Opinion:
- [By Alex Sirois]
ESG investors know that there are multiple ways to direct their investment capital in order to help. One such way is to invest in the clean energy sector at large. So, for those investors alarmed by the findings in that report, here are several clean energy stocks to buy to help make a change.
Brookfield Renewable Corp. (NYSE:BEPC) Hannon Armstrong Sustainable Infrastructure Capital (NYSE:HASI) Renewable Energy Group (NASDAQ:REGI) Enphase Energy (NASDAQ:ENPH) Sunrun (NASDAQ:RUN) Ameresco (NYSE:AMRC) Array Technologies (NASDAQ:ARRY)
Clean Energy Stocks for ‘Code Red’: Brookfield Renewable Corp. (BEPC) Source: IgorGolovniov / Shutterstock.com
Brookfield Renewable Corporation is a business structure that issues securities designed to provide returns similar to those in its parent company, Brookfield Renewable Partners (NYSE:BEP).
Top 10 Medical Stocks To Invest In Right Now: iShares MSCI All Country Asia ex Japan Index Fund(AAXJ)
iShares MSCI All Country Asia ex Japan ETF (the Fund), formerly The iShares MSCI All Country Asia ex Japan Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance, of the MSCI All Country Asia ex Japan Index (the Index). The Index is a free-float adjusted market capitalization index designed to measure equity market performance of the 12 countries, such as Australia, China, Honk Kong, India, Indonesia, Malaysia, New Zealand, the Philippines, Singapore, South Korea, Taiwan and Thailand. The Fund generally invests at least 90% of its assets in securities of the Underlying Index and in depositary receipts representing securities of the Underlying Index. BlackRock Fund Advisors (BFA) serves as the investment advisor to the Fund. Advisors’ Opinion:
- [By Shane Hupp]
iShares MSCI All Country Asia ex Japan ETF (NASDAQ:AAXJ) was the target of a significant growth in short interest during the month of September. As of September 14th, there was short interest totalling 875,043 shares, a growth of 53.0% from the August 31st total of 571,842 shares. Based on an average daily volume of 1,752,942 shares, the days-to-cover ratio is presently 0.5 days.
Top 10 Medical Stocks To Invest In Right Now: Education Realty Trust Inc.(EDR)
Education Realty Trust, Inc. (“EdR”) is a self-managed and self-advised company incorporated in the state of Maryland in July 2004 to develop, acquire, own and manage collegiate housing communities located near university campuses. We were formed to continue and expand upon the collegiate housing business of Allen & O’Hara, Inc., a company with over 40 years of experience as an owner, manager and developer of collegiate housing. We selectively develop collegiate housing communities for our own account and also provide third-party management services as well as third-party development consulting services on collegiate housing development projects for universities and other third parties. As of December 31, 2015, we owned 59 collegiate housing communities located in 21 states containing 30,400 beds in 11,679 apartment units on or near 37 university campuses. Advisors’ Opinion:
- [By Shane Hupp]
E-Dinar Coin (CURRENCY:EDR) traded up 6% against the US dollar during the twenty-four hour period ending at 21:00 PM Eastern on February 20th. Over the last week, E-Dinar Coin has traded 3.4% higher against the US dollar. One E-Dinar Coin coin can currently be purchased for about $0.0074 or 0.00000186 BTC on major exchanges including LocalTrade, Livecoin, Exrates and YoBit. E-Dinar Coin has a total market cap of $6.55 million and approximately $2.04 million worth of E-Dinar Coin was traded on exchanges in the last 24 hours.
- [By Logan Wallace]
E-Dinar Coin (CURRENCY:EDR) traded flat against the US dollar during the 1 day period ending at 12:00 PM ET on October 3rd. Over the last seven days, E-Dinar Coin has traded up 3.2% against the US dollar. One E-Dinar Coin coin can currently be purchased for about $0.0105 or 0.00000162 BTC on popular cryptocurrency exchanges including Livecoin, Exrates, LocalTrade and YoBit. E-Dinar Coin has a market cap of $9.34 million and $202,866.00 worth of E-Dinar Coin was traded on exchanges in the last day.
- [By Ethan Ryder]
Education Realty Trust, Inc. (NYSE:EDR) has earned a consensus recommendation of “Hold” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $41.93.
- [By Ethan Ryder]
Endor Protocol (CURRENCY:EDR) traded up 4.7% against the US dollar during the twenty-four hour period ending at 13:00 PM ET on September 23rd. Over the last week, Endor Protocol has traded 18.1% higher against the US dollar. One Endor Protocol token can currently be bought for approximately $0.0718 or 0.00001074 BTC on exchanges including Bilaxy, Kucoin, IDEX and DEx.top. Endor Protocol has a total market cap of $38.92 million and $776,781.00 worth of Endor Protocol was traded on exchanges in the last 24 hours.
Top 10 Medical Stocks To Invest In Right Now: Realogy Holdings Corp.(RLGY)
The following table represents key business drivers for the periods set forth below:
Six Months Ended June 30, Year Ended December 31, 2012 2011 2011 2010 2009 Operating Statistics: Real Estate Franchise Services (1) Closed homesale sides (2) 471,229 435,688 909,610 922,341 983,516 Average homesale price (3) $ 205,967 $ 198,513 $ 198,268 $ 198,076 $ 190,406 Average homesale broker commission rate (4) 2.55 % 2.55 % 2. Advisors’ Opinion:
- [By George Budwell, Chuck Saletta, and Todd Campbell]
Armed with this insight, we asked three of our Motley Fool contributors which top small-cap stocks have their attention right now. They named AcelRx Pharmaceuticals (NASDAQ:ACRX), Realogy Holdings (NYSE:RLGY), and Regenxbio Inc. (NASDAQ:RGNX). Read on to find out why.
- [By Max Byerly]
Get a free copy of the Zacks research report on Realogy (RLGY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 10 Medical Stocks To Invest In Right Now: Dermira, Inc.(DERM)
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The companys late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe plaque psoriasis; DRM04, a small-molecule anticholinergic product that has completed a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
